PT Royal Medicalink Pharmalab
Indonesia's 1st Indigenous ProbioticPT Royal Medicalink Pharmalab

The Future of Gut Health, Engineered from Indonesian Biodiversity.

Vipilac® introduces Lactiplantibacillus plantarum Dad-13—an indigenous probiotic strain isolated from traditional Minangkabau dadih and backed by 20+ years of clinical research with Universitas Gadjah Mada (UGM). Engineered specifically for tropical gut microflora.

Explore Clinical Trials (RCT)How It Works
BPOM RI
Izin Edar Resmi
HALAL MUI
ID732100320428
CPOTB GMP
Standar Industri
TKDN P3DN
Kemandirian Farmasi
L. plantarum Dad-13
2–8°C Cold Chain
Maskot Royal Medica membawa Produk Vipilac Probiotik Indigenous
Box, 30 Capsules1×10⁹ CFU
BPOM RegisteredPOM SD.233076131
1×10⁹
CFU per Kapsul

Potensi terapeutik aktif terjamin hingga kedaluwarsa

20+ Thn
Riset Ilmiah UGM

20+ Publikasi ilmiah terindeks Scopus & PubMed

55%
Subjek Turun E. coli

Dan penurunan coliform pada 75% subjek penelitian

100%
Bahan Baku Mandiri

Kemandirian farmasi nasional tanpa impor

SAINS KESESUAIAN BIOLOGIS (HOST ECOLOGY)

Why Indonesian Guts Need an Indigenous Probiotic, Not an Imported Strain

Over 95% of probiotics circulating in Indonesia are imported from Western temperate countries with data primarily derived from non-tropical populations. As an indigenous strain isolated from traditional fermented food and clinically proven in Indonesian cohorts, L. plantarum Dad-13 demonstrates superior biological host relevance and colonization affinity for tropical gut ecologies.

Conventional Imported Probiotics

Strains from Sweden, Canada, Denmark

  • Isolated from Western climate populations:Accustomed to diets high in cold dairy products and low in tropical spices and fibers.
  • Limited tropical adaptation data:Lacks local clinical validation in Indonesian dietary patterns, often leading to rapid wash-out without colonizing.
  • Sub-therapeutic concentration:Mostly contains unstandardized or sub-optimal CFU, highly susceptible to eradication by gastric acid.
  • High import dependency:Does not contribute to national pharmaceutical sovereignty or domestic raw material supply chains.
Tropical Gut CompatibilitySub-optimal
Host-Specific Tropical Formulation

Vipilac® Indigenous L. plantarum Dad-13

Isolated from Minangkabau Dadih, West Sumatra

  • Perfect tropical microbiome adaptation:Naturally resistant to Indonesian dietary patterns (spiced, rich in coconut milk, and spicy culinary habits).
  • Persistent mucosal colonization:Clinically proven to adhere strongly to intestinal epithelial cells of Indonesians, establishing active protective colonies.
  • Therapeutic dose of 1×10⁹ CFU:Ensures viable bacterial count surviving through gastrointestinal transit far surpasses clinical efficacy thresholds.
  • 100% National pharmaceutical sovereignty:Researched and developed by UGM scientific consortium and produced at Royal Medica CPOTB facility in Makassar.
UGM Research Consortium & CPOTB Makassar5x Stronger Retention
MECHANISM OF ACTION (MOA)

The 4-Stage Biological Cascade in Your Gut

From surviving intense stomach acidity to modulating systemic immunity, learn how 1×10⁹ viable Vipilac bacteria work with precision.

PHASE 01 • ACTIVE
01
pH 2.0 RESISTANT
Tested Viability at pH 2.0

Gastric Acid & Bile Resistance

Unlike fragile strains that degrade in gastric acid, L. plantarum Dad-13 survives the harsh pH 2.0 stomach environment and bile salts, entering the duodenum fully alive.

Survival Rate >99%Duodenum Node
02
ADHESION RATIO
Persistent Indigenous Attachment

Mucosal Adhesion & Colonization

Possesses specialized surface proteins that bind tightly to Indonesian enterocytes, establishing long-term colonies rather than being quickly flushed out.

Native AffinityEnterosit Layer
03
ANTIMICROBIAL
Suppresses E. coli in 55% & Coliform in 75% of Subjects

Bacteriocin Pathogen Suppression

Secretes natural antimicrobial peptides (bacteriocins) that actively eradicate pathogens like E. coli, Salmonella, and opportunistic dysbiosis agents.

Bio-InhibitionLuminal Defense
04
70% GUT-AXIS
Boosts SCFA (Acetate, Propionate, Butyrate)

Gut-Immune Axis Modulation

Produces essential Short-Chain Fatty Acids that nourish colonocytes, reduce systemic inflammation (CRP/IL-6), and empower 70% of the body immune defenses situated in the gut.

SCFA CascadeSystemic Health
Evidence-Based Medicine • 3 RCT Trials & Mucosal Studies

Validated by Rigorous Clinical Trials in Indonesian Cohorts

Every therapeutic efficacy is backed by peer-reviewed randomized controlled trials in Indonesian cohorts and robust mucosal barrier characterization published in reputable international medical journals.

Double-Blind RCT DesignPeer-Reviewed International JournalsDewan Etik Medis Resmi Terverifikasi
School Children RCT • 65 Days
Faculty of Agricultural Technology & Medicine, UGMOfficial Collaborative Research

Significant Suppression of Pathogenic E. coli & Fecal Coliform Bacteria

55%

Subjects with E. coli Drop (11/20)

75%

Subjects with Coliform Drop (15/20)

+46%

Propionate SCFA Elevation

+28%

Butyrate (Mucosal Shield)

A double-blind, randomized controlled trial on school children demonstrated a reduction in E. coli in 55% of subjects and coliform in 75% of subjects, while stimulating short-chain fatty acids (SCFAs) that safeguard the intestinal mucosal barrier.
Publication: Banin, M.M., Utami, T., Cahyanto, M.N., Widada, J. & Rahayu, E.S., Int J Probiotics Prebiotics (2019)
Download Journal (PDF)
Type 2 Diabetes Mellitus RCT • 11 Weeks
Center for Food and Nutrition Studies, UGM & FK-KMKOfficial Collaborative Research

Metabolic Glycemic Control Improvement & Blood SCFA Augmentation

-12%

Intervention HbA1c Trend

+21%

Total Circulating Blood SCFA

p < 0.05

SCFA Elevation (p < 0.05)

Zero

Adverse Side Effects (0 Reported)

An 11-week randomized trial demonstrated that microbiota modulation with indigenous Dad-13 showed a favorable trend in HbA1c reduction (from ~9.3% to ~8.3%) within the intervention group, alongside a statistically significant +21% surge in circulating SCFAs (p < 0.05) with zero adverse effects.
Publication: Rustanti, N., Murdiati, A., Juffrie, M. & Rahayu, E.S., Microorganisms MDPI (2022)
Download MDPI Paper (PDF)
ICU Critical Sepsis RCT • 4 Days Hospitalized
RSUP H. Adam Malik & Faculty of Medicine, USU MedanOfficial Collaborative Research

Drastic Reduction in Acute Inflammatory Biomarkers (CRP & Procalcitonin)

-30%

CRP Level Dropped (Control: +811%!)

-17%

Procalcitonin (PCT) Reduction

-4%

Interleukin-6 Controlled (Control: +45%)

ICU

Proven in Intensive Care Unit

In hospitalized critical sepsis ICU patients, adjuvant administration of Dad-13 modulated the gut-immune axis, dropping CRP inflammatory biomarkers by 30% within 4 days, whereas the non-probiotic standard care control group surged up to +811%.
Publication: Zulkarnain, Z., Hanafie, A., Lubis, A.P. & Yunanda, Y., Research Square / Springer Nature (2025)
Download ICU Journal (PDF)
Preclinical & Mucosal Integrity Characterization
Microbiology Research Laboratory UGM & RMPOfficial Collaborative Research

Strong Antibacterial Inhibition Zone & Mucosal Erosion Protection

26.84mm

E. coli Inhibition Zone (>9mm Strong)

100%

Intact Mucosal Integrity Without Erosion

pH 2.0

Gastric Acid Survivability pH 2

0 Gen

Antibiotic Resistance Transfer (Zero Risk)

In-vitro and mucosal barrier assays demonstrated strong bactericidal activity with clear zones over 26mm against gut pathogens without damaging intestinal villi walls, validating its biocompatibility and anti-pathogen capacity.
Publication: Ariska et al., In Vivo Anti-Bacterial Multi-strain Assessment (2024)
Download Lab Study (PDF)
SCIENTIFIC COMPARISON TRANSPARENCY

Transparent Comparison: Vipilac® vs Conventional Probiotics

Compare the scientific facts. See why medical specialists and informed consumers are switching to Indonesia’s proud indigenous probiotic innovation.

Parameter 01

Origin of Bacterial Strain

Biological source of microbial inoculum isolation

Vipilac®⭐ Rekomendasi

Indigenous Indonesia (Dadih Minangkabau)

100% Proven Local Strain
Conventional Imported

Imported (Sweden, Canada, Denmark)

Subtropical western ecosystem microbes

Parameter 02

Active CFU Concentration / Capsule

Viable colony forming units per serving

Vipilac®⭐ Rekomendasi

1×10⁹ CFU Clinically Tested

Full Therapeutic DosageBased on Clinical Trials
Conventional Imported

Sub-optimal CFU / Unstandardized

Susceptible to gastric acid & bile degradation

Parameter 03

Clinical Trials on Indonesian Population

Direct RCT validation on local demographics

Vipilac®⭐ Rekomendasi

YES (20+ Years UGM: Children, T2DM, ICU)

Proven Multi-Cohort Open Data
Conventional Imported

NO (Tested only on western populations)

Different genomic & gut microbiota profiles

Parameter 04

Adaptation to Tropical & Spicy Diet

Tolerance to capsaicin, acid, and coconut milk

Vipilac®⭐ Rekomendasi

Optimal (Co-evolved with tropical gut microbiota)

Highly Compatible & Resilient
Conventional Imported

Less Adaptive (Subtropical/Western strains)

Western strains prone to stress & gut wash-out

Parameter 05

Transferable Antibiotic Resistance Risk

Antimicrobial Resistance (AMR) mutation safety

Vipilac®⭐ Rekomendasi

Zero (Validated by Whole Genome Sequencing / WGS)

Whole Genome Sequenced (WGS)
Conventional Imported

Variable (Not all have open genomic data)

Most lack publicly published genome data

Parameter 06

Domestic Manufacturing Independence (TKDN)

Supply chain sovereignty and pharmaceutical facility

Vipilac®⭐ Rekomendasi

100% In-house CPOTB Facility in Makassar

High TKDN & Independent Research
Conventional Imported

Imported Finished Products / Re-packing

Vulnerable to global supply chain disruptions

Parameter 07

Official Halal Certification

Regulatory halal compliance of fermentation media

Vipilac®⭐ Rekomendasi

Resmi BPJPH ID73210032042811025 & MUI

Active Official Certification
Conventional Imported

Variable / Many lack local BPJPH certification

Uses fermentation media not yet verified by BPJPH

Parameter 08

Therapeutic Cold-Chain (2–8°C) Guarantee

Medical logistics cold storage system integrity

Vipilac®⭐ Rekomendasi

Hospital-Standard Cold-Chain Protocol Guaranteed

Hospital Cold-Chain Protocol
Conventional Imported

Room temperature shelf (higher cell death)

Bacterial viability plummets in tropical ambient heat

Supported by 20+ Years Research Consortium of Universitas Gadjah Mada (UGM) & CPOTB Standard Facilities of PT Royal Medicalink Pharmalab Makassar.

Sertifikasi BPOM CPOTB

UGM Research Consortium

Scientifically tested and validated by leading microbiome scientists.

CPOTB Pharmaceutical Standard

Good Manufacturing Practice certification from BPOM RI.

100% RCT-Based

Transparent publication of Randomized Controlled Trial data.

Storage Protocol & Dosage Guide

Cold-Chain Preservation & Usage Guide

Ensuring optimal viability of 1×10⁹ live CFU cells from our facility to your digestive tract, backed by medical administration guidelines.

2°C – 8°C • TERJAMIN AKTIF

The Importance of Cold Chain (2–8°C)

Medical Standard for 1×10⁹ Active CFU Viability

Probiotic bacteria are live vegetative cells sensitive to tropical heat. Cold storage at 2–8°C maintains bacteria in a natural dormant state, slowing cell metabolism so 1×10⁹ CFU remain fully viable until expiry.

Natural Dormancy

Bacteria preserve energy reserves until reaching the gut.

Insulated Delivery

Equipped with cold packs & thermal pouch during transit.

Store in the refrigerator door / chiller. Do not freeze in the freezer.
30 Capsules • 1-Month Program

Dosage & Clinical Administration

Daily Maintenance & Targeted Therapy Guidelines

Adults (Maintenance & Immunity)1 Kapsul / Hari

1 capsule per day, consumed after meals with room-temperature water.

Post-Antibiotics / IBS / Diarrhea1–2 Kapsul / Hari

1–2 capsules per day. Allow a 2-hour interval after antibiotic intake.

Children & Special PopulationsMedical Advice

As directed by a pediatrician / specialist. Capsule may be opened and mixed into room-temperature water or milk.

Safe for long-term daily consumption without causing dependency.
FREQUENTLY ASKED QUESTIONS

Frequently Asked Questions About Vipilac®

Comprehensive, medically validated information to support your therapeutic needs.

Vipilac is Indonesia first clinical-grade probiotic supplement formulated with Lactiplantibacillus plantarum Dad-13. This strain was isolated directly from Dadih (traditional fermented buffalo milk from West Sumatra) and developed through 20+ years of scientific research by Universitas Gadjah Mada (UGM). Unlike imported probiotics, Vipilac bacterial raw materials are fully researched, cultured, and produced domestically by PT Royal Medicalink Pharmalab in Makassar under CPOTB (Indonesia GMP) standards.
Indonesian Pharmaceutical Sovereignty Starts Here

Restore the Natural Balance of Your Gut Microbiome.

Available at authorized partner pharmacies, hospitals, or consult your clinical therapy needs directly with the PT Royal Medicalink Pharmalab medical team.

Contact UsDownload Clinical Trial Paper (PDF)
Produced by PT Royal Medicalink Pharmalab
Makassar, South Sulawesi
UGM Research Consortium
Vipilac® 30 Capsules
Rp 290.000/ Box
Order / Consult